Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 19, 2019
Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the initiation of a Phase 2 clinical trial evaluating NCX 4251, its novel ...
March 19, 2019
VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment
TEL AVIV, Israel, March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced the presentation of human data indicating that the viral anti-cancer ...
March 19, 2019
Altimmune Announces Positive Results from NasoVAX Extension Study
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension ...
March 19, 2019
Reducer Featured in Presentation at American College of Cardiology's Annual Meeting
VANCOUVER, March 19, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies ...
March 19, 2019
Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan
EMERYVILLE, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered ...
March 19, 2019
Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Urovant Sciences (UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced positive topline results from EMPOWUR, an ...
March 19, 2019
FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients
FLORHAM PARK, N.J., March 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
March 15, 2019
Nicox signs agreement for ZERVIATE in China for up to €17 million in milestone payments plus royalties
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Ocumension Therapeutics today announced they have entered into an exclusive license agreement for the ...
March 15, 2019
Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
March 15, 2019
AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)
BROOKLYN, N.Y., March 15, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
March 15, 2019
Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference
NEW YORK, March 15, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will present a corporate ...
March 15, 2019
Outlook Therapeutics Announces Reverse Stock Split
CRANBURY, N.J., March 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today that its Board of Directors has approved a 1-for-8 ...
March 15, 2019
Neovasc Announces Closing of $5 Million Public Offering of Common Shares
VANCOUVER , March 15, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously ...
March 12, 2019
MediWound Announces Executive Leadership Changes
YAVNE, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe ...
March 12, 2019
AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
March 12, 2019
Krystal Biotech Reports 2018 Financial Results and Business Progress
PITTSBURGH, March 12, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases announced financial results ...
March 12, 2019
Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18
HAIFA, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today ...
March 12, 2019
Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
TEL AVIV, Israel, March 12, 2019 /PRNewswire/ --  Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...
March 12, 2019
Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population
SALT LAKE CITY, March 12, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the ...
March 12, 2019
CymaBay Therapeutics to Present at Upcoming Investor Conferences in March
NEWARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies ...
Page 6 of 138